"STRONGER TOGETHER": SWITZERLAND CHAMPIONS INTERNATIONAL PARTNERSHIPS AS KEY TO ACCELERATED INNOVATION", ONCE AGAIN SWITZERLAND IS SHOWCASING ITS BIOTECH EXCELLENCE AT BIO INTERNATIONAL IN BOSTON 16-19 JUNE, 2025
Swiss biotech excellence returns to BIO 2025 in Boston, where Switzerland Global Enterprise presents 45 cutting-edge Swiss companies at the SWISS BIOTECH pavilion, booth #2345, showcasing the country's healthcare innovation leadership.
ZURICH, June 11, 2025 /PRNewswire/ -- The represented biotech companies primarily focus on therapeutics development across oncology, respiratory diseases, rare diseases, and CNS disorders, alongside advanced drug discovery technologies including 3D microtissues, transcriptomics, and novel delivery systems.
Switzerland's biotech sector thrives on international collaboration, with 80% of Swiss biotech patents resulting from partnerships rather than competition. The country leverages its diverse talent pool and takes leadership roles in global initiatives like the 47-country Eureka network (chaired by Innosuisse) and the Access Consortium for joint regulatory approvals. This collaborative approach spans from research to market access, positioning Switzerland as a valuable global partner in solving health care challenges.
In short: "Switzerland's collaborative model offers a compelling counterproposal to 'me first' approaches, fostering international knowledge exchange to become stronger, faster and smarter together", says Michael Altorfer CEO, Swiss Biotech Association.
Switzerland Global Enterprise with its partner Swissnex in Boston and New York will be hosting a Swiss "Wine and Cheese" reception on Tuesday June 17th from 5pm to 6:30pm at the Swiss Pavilion, booth #2345.
| Global leader in scalable transcriptomics solutions for screening applications. |
| Developing and supplying peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues (xPhore™ platform). |
| Acts as a life sciences cluster promoting networking and collaboration in the BioAlps community. |
| Provides solutions in bioprocess engineering, ranging from development to production scale. |
| Operates a life sciences campus that supports innovation and development in the healthcare and biotech sectors. |
| Providing cutting-edge bioreactor technologies that simplify and automate cell-based therapies. |
| Promotes Switzerland as a prime location for business and investment. |
| Developing highly specific antibody therapeutics to target intracellular proteins presented on the major histocompatibility complex (MHC). |
| Semiconductor manufacturer specialized in the design and production of ultra-low power, low voltage integrated circuits (IC) for battery-operated and field-powered applications. |
| Utilizes cutting edge technology to analyze chiral molecules and biologics. |
| Offers comprehensive property management services across Switzerland. |
| Developing a patented oral topical therapy to cure and prevent oral mucositis and oral candidiasis. |
| Develops and produces 3D microtissues for drug discovery and toxicity testing. |
| Offers audit, tax, and advisory services to help organizations. |
| They provide a unique platform technology that enable manufacturing of clinical-grade cell products at scale, through automation and standardization. |
| Develops a new class of custom-built protein therapeutics known as DARPin® molecules. |
| Revolutionizing the marking of cancer stem cells by offering a specific biomarker for several cancers, including lung, breast and colon |
| Proven vaccine technology, focused on developing R&D assets and establishing partnerships to leverage the value of the technology to help protect health. |
| Developing selective immunomodulators, which regulate T cell immune responses that play a key role in graft rejection and autoimmunity, while leaving the protective responses against infections and vaccination intact. |
| Quality assurance consulting firm offering tailored solutions to the pharma industry aiming at enhancing compliance and improving processes in the execution of clinical trials. |
| Engages in the research, development, and marketing of medicines in respiratory and vascular diseases. |
| Focuses on developing precision drugs for the treatment of severe and rare diseases. |
| Breaking new ground in the treatment of metabolic diseases |
| Proprietary technology represents a significant advancement in antimicrobial therapies, setting a new standard in the industry. |
| Provides high-tech laboratory services and research facilities for life sciences companies. |
| Offers clinical trial management and pharmaceutical consulting services. |
| Specializes in the assessment and valuation of growth companies in the life sciences and technology sectors. |
| Dedicated to advancing mitochondrial transplantation therapy to treat acute and chronic degenerative diseases. |
| Provides high-throughput screening services using innovative fluorescence-based technologies. |
| Develops the first Organism-on-Chip technology for automated and ethical testing of drugs and chemicals. |
| Specializes in microbiome analytics and solutions for healthcare and agricultural applications. |
| Focuses on the development of breakthrough therapies for the treatment of central nervous system disorders. |
| Offers digital solutions to enhance the efficiency and effectiveness of healthcare and medical management. |
| Engages in the development of innovative oncology treatments. |
| Provides infrastructure and support for startups and established companies in the life sciences sector. |
| Specializes in virtual reality solutions, primarily for therapeutic and rehabilitation applications. |
| Produces biopharmaceuticals using advanced cell line engineering and protein production technologies. |
| Offers workshops and training in immunotherapy and biological production. |
| Develops chitosan-based formulations to enhance the delivery of biopharmaceuticals. |
| Specializes in developing therapies for respiratory diseases. |
| Supports economic development in Valais, particularly in the sectors of technology, education, and innovation. |
| Works on bioprocesses that utilize human stem cells for regenerative medicine. |
| Provides laboratory services, R&D, and consulting to foster innovation in biotechnology. |
| Offers services in drug development and manufacturing, with a focus on sustainable practices. |
| Ymmunobio AG is a preclinical stage biotechnology company developing a novel class of immune oncology therapeutic antibodies. |
The SWISS BIOTECH companies will be available for media and partner interviews the entire week.
Media Contacts | Partnerships & Business Development |
Lisette Müry | Karine J. Wittmer |
Trade Fairs | Foreign Direct Investment |
Export Promotion & Global Network | Trade Commissioner |
Bettina Thomas | Sean Powers |
About Switzerland Global Enterprise
Switzerland Global Enterprise (S-GE) is the official Swiss organization for export and investment promotion with around 200 employees at locations throughout Switzerland and overseas. S-GE supports Swiss SMEs in their international business and helps innovative foreign companies to settle in Switzerland. In doing so, we rely on a unique network of national and international partners. This allows us to create added value for our customers and prosperity for Switzerland. As a non-profit organization, we provide a public service for our clients on behalf of the Swiss Confederation (State Secretariat for Economic Affairs SECO) and the cantons. We operate our 27 offices, the so-called Swiss Business Hubs, and Trade Points, in 31 countries jointly with the Federal Department of Foreign Affairs (FDFA). Thanks to our global network of partners, we also support our customers in many other countries.
SOURCE Swiss Business Hub USA
Share this article